Pediatric high-grade gliomas are aggressive brain tumors with a poor prognosis. New research suggests that platelet-derived growth factor receptor alpha (PDGFRA) could be a potential therapeutic target and provides the first real-world clinical data supporting the use of a PDGFRA inhibitor to treat certain patients with these tumors.

From Mariela Filbin and colleagues, joint first authors Lisa Mayr, Sina Neyazi, Kallen Schwark, and Maria Trissal. Featured in Boston Children’s Hospital Answers.